Canada and the European Union have banned the use of Bovine Recombinant Growth Hormone (rBGH), citing its toxicity to both cows and humans, but the US Food and Drug Administration approved rBGH use for US dairy cows.
rBGH a genetically engineered synthetic
hormone, mimics a naturally occurring hormone released when a
cow is pregnant, which allows the cow to produce milk for her
calf. When rBGH is injected into a cow, nature runs wild, causing
the cow's milk output to increase. Nutritional energy that is
supposed to sustain the entire cow becomes almost entirely dedicated
to milk production. Vital nutrients are leached from other parts
of her body, causing painful udder infections and crippling lameness.
In addition, rBGH injected cows are much more likely to suffer
infertility and gastrointestinal disorders. Because rBGH use increases
the incidence of disease a rBGH-injected
cow requires greater amounts of antibiotics than an rBGH-free
cow. Increased antibiotic usage may lead to resistance to antimicrobials,
having dire consequences for the health of both humans and cows.
After more than nine years of study that took into account the findings of two independent advisory panels, Health Canada (the FDA's Canadian counterpart) made the decision to ban the hormone, citing greatly increased health risks to cows and potential health risks for humans exposed to rBGH. Canadian researchers reported that "long-term toxicology studies to ascertain human safety" must be conducted, as their research indicated that rBGH may cause "sterility, infertility, birth defects, cancer and immunological derangements" in humans. Other recent studies, as reported in the Journals Science (1/23/98) and The Lancet (5/9/98) have linked IGF-I (Insulin-like Growth Factor), high levels of which are present in milk produced with rBGH, to much increased incidence of prostate and breast cancer.
The European Union has enacted an rBGH moratorium, due to expire in 2000, based on European studies that concurred with Health Canada's findings. In addition, a recent European Commission on Consumer Health and Protection study concluded that rBGH should not be used in dairy cows, as its use seriously compromises a cow's health and well-being.

Why the US needs to increase milk production is puzzling. Every year since the mid-1950s, the US has produced far more milk than its citizens can consume. According to the Ecologist (vol. 28, no. 5), since 1980 the US government has spent a whopping 18 billion dollars sopping up America's milk surplus in order to prevent milk prices from plummeting.
How and why approval of rBGH occurred and is being upheld,
seems not so much a question answered
by sound science or interest in the public's welfare, but by corporate
patronage. If rBGH's approval were to be rescinded, the Monsanto
corporation stands to lose $300 to $500 million a year in sales
of its rBGH product, Posilac. Upper echelons of Monsanto and FDA
management are constantly interchanged. Many of Monsanto's top
brass were once employed by the FDA, and vice versa. For example,
Margaret Miller, the FDA's Director of Food Safety, is now "reviewing"
her own rBGH research done while she was a Monsanto employee.
Monsanto attorney Michael Taylor was hired by the FDA to fast-track
rBGH through the approval process.
In order to approve the growth hormone, the FDA violated its own
guidelines on several occasions. According to FDA literature,
approval of a drug "requires pharmaceutical companies to
submit all studies they conducted [and] all the raw data form
the basis of the approval of the product...". The FDA never
reviewed all of Monsanto's data, disregarded the Canadian ban
decision, and approved rBGH based solely on information presented
in Monsanto's own project summary.
The FDA website states that the "elimination of violative residues in meat and milk" is of utmost importance. By ignoring warnings from both Europe and Canada, the FDA endangers the well-being of Americans and their dairy cows.
AWI Quarterly, Spring 1999, Vol. 48, No. 2